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Abstract
 
Experiments in nonobese diabetic (NOD) mice that lacked expression of glutamic acid decar-
 
boxylase (GAD) in 
 
 
 
 cells have suggested that GAD represents an autoantigen essential for
initiating and maintaining the diabetogenic immune response. Several attempts of inducing
GAD-specific recessive tolerance to support this hypothesis have failed. Here we report on
successful tolerance induction by expressing a modified form of GAD under control of the
invariant chain promoter resulting in efficient epitope display. In spite of specific tolerance
insulitis and diabetes occurred with normal kinetics indicating that GAD is not an essential
autoantigen in the pathogenesis of diabetes.
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Introduction
 
Failure of self-tolerance can result in tissue-specific auto-
immunity. Various types of experimental autoimmune
phenomena can be elicited in rodents by deliberate im-
munization with particular self-antigens, suggesting that a
breakdown of tolerance to a single self-antigen can be suffi-
cient to trigger an autoimmune organ destruction. How-
ever, it is still a matter of debate in how far such a scenario
is representative of the natural etiology of spontaneous au-
toimmune diseases, i.e., whether one distinct self-antigen is
obligatorily involved in the initiation and, perhaps, even
the perpetuation of autoimmune tissue destruction. The
eventual existence of such 
 
essential
 
 autoantigens is of great
clinical importance, as they represent promising targets for
therapeutic intervention with specific, tolerogenic regi-
mens that avoid the side-effects of nonspecific immune
suppressive strategies. The definition of an essential autoan-
tigen can be based on two experimentally testable predic-
tions: (a) specific induction of tolerance to the respective
self-antigen and/or (b) ablation of expression of the antigen
in the target organ would prevent autoimmunity. Here, we
have used the NOD mouse model of insulin-dependent di-
abetes mellitus (IDDM),
 
*
 
 a well characterized model of
spontaneous autoimmunity, to address the role of glutamic
acid decarboxylase (GAD) 65 as an autoantigen in IDDM.
IDDM results from T cell–mediated destruction of insu-
lin producing pancreatic 
 
 
 
 cells (1). The NOD mouse is a
widely used animal model of IDDM sharing major disease
characteristics with the human disease (2). Because
 
CD4
 
 
 
T cell responses and auto-antibodies against GAD65
are among the first to be detected in NOD mice (3, 4) and
humans (5) it was suggested that GAD65 is a major auto-
antigen in the initiation of the immune response against 
 
 
 
cells. In fact the disease could be prevented in NOD mice
by intrathymic (4), intravenous (3), nasal (6), and oral (7)
administration of GAD65. The mechanisms of tolerance
remained elusive in these experiments, and protection may
have resulted from induction of regulatory T cells (domi-
nant tolerance) rather than elimination of GAD-reactive
T cells (recessive tolerance; reference 8). Additional strong
evidence indicating that GAD may be an essential autoan-
tigen was provided by Yoon and coworkers, who pre-
vented IDDM by silencing GAD expression with a 
 
 
 
 cell
specific antisense approach (9). Strikingly, GADless islets
transplanted into diabetic animals were protected from au-
toimmune destruction suggesting that GAD is not only es-
sential for initiating but also for maintaining an ongoing
anti-
 
 
 
 cell immune response (9). The various findings
have led to an initiative for clinical trials using GAD65-
specific tolerance.
Nevertheless the results of Yoon et al. have met with
considerable skepticism (9, 10), e.g., it was argued that ab-
sence of GAD expression may have rendered the 
 
 
 
 cells
resistant to apoptosis or may have induced an unknown
protective metabolic effect. Another finding that argues
against an essential role of GAD in IDDM is that diabetes
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Abbreviations used in this paper:
 
 DC, dendritic cell; GAD, glutamic acid
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developed normally in GAD65 knockout NOD mice (11),
although the interpretation of this observation in compli-
cated by the fact that GAD65 shares several epitopes with
GAD67. Several attempts to induce specific tolerance by
transgenic overexpression of GAD65 have failed and thus
could not address the question whether or not GAD repre-
sents an essential autoantigen (12, 13). This failure could be
due to possible resistance of NOD mice to tolerance induc-
tion (13, 14) or the fact that GAD epitopes were insuffi-
ciently presented (12). It was the aim of the present study
to express a suitably modified GAD construct with en-
hanced routing to the class II MHC loading pathway in or-
der to induce GAD-specific tolerance.
 
Materials and Methods
 
Mice
 
NOD/Ltj mice were purchased from The Jackson Laboratory
or bred in our facility. Diabetes incidence in females was 90%.
NOR, C57/B6, and Balb/c were bred and maintained in the
DFCI animal facility. For timed mating experiments animals were
mated and carefully examined for plugs. The morning when
plugs were detected was counted as day 0.5. Diabetes develop-
ment was monitored by tail bleeding analyzed with Accu-Chek
Advantage device (Roche Diagnostics). Two subsequent mea-
surements 
 
 
 
200 mg/dl were considered to indicate IDDM. All
animal experiments were performed according to NIH guidelines
and experimental protocols were approved by the animal care and
user committee of the DFCI.
 
Antibodies
 
Antibodies used: anti-CD4-APC, anti-CD4-biotin, anti-
CD8-PE, anti-CD8-biotin, anti-CD3-biotin, anti-CD19-PE,
anti-B220-Cyc, anti-TCR
 
 
 
-PE, anti-CD11b-PE, anti-GR1-PE,
and anti-CD11c-biotin (all BD Biosciences). Cells were analyzed
on a four color FACSCalibur™ (Becton Dickinson).
 
Generation of GAD65 Transgenic Mice
 
The H-2K
 
b
 
-leader was fused to GAD65, from which the first
44 amino acids were deleted. The H-2Kb-leader GAD65
boundaries are shown in Fig. 1 B. The H-2Kb-leader was gener-
ated as double stranded oligonucleotide and cloned in via KpnI,
NcoI restriction sites. The plasmid containing murine GAD65
was kindly provided by A. Lehuen (INSERM, Paris, France).
The active site of GAD65 was inactivated by site directed mu-
tagenesis (K396G) and the carboxyterminal end was fused to the
LAMP1 cytoplasmic tail containing the Tyr-x-x-hydrophob
motif for routing the protein into late endosomes, lysosomes
(Fig. 1 B; reference 15). The Lamp1-GAD65 boundaries are
shown in Fig. 1 B. The fragment was cloned in via HindIII,
BamHI restriction sites. The coding sequence was followed by
an 
 
 
 
-globin polyadenylation signal. Expression of the construct
was driven by a hybrid invariant chain promotor (16). The
purified DNA was injected into fertilized NOD oocytes and
reimplanted into foster mothers. Offspring was screened by
PCR of genomic DNA using primers GAD65 (5
 
 
 
-ATGGTGT-
TTGATGGGAAGCCTC-3
 
 
 
) and LAMPrv (5
 
 
 
-TGCAAAG-
CTTATCGATGGATCCGTTAACGCTATCTCTGGTGCA-
CCTGCCCAC-3
 
 
 
) for GAD65 transgenic animals.
 
Expression Analysis
 
Total RNA was prepared from frozen tissue samples using
TRIZOL (Life Technologies). 2 
 
 
 
g total RNA was reverse tran-
scribed using oligo-dT
 
12–15
 
 priming. Fivefold serial dilutions of
cDNA were amplified using forward primer (5
 
 
 
-AGACACA-
CAGCAGCAGCAGCAGC-3
 
 
 
) and reverse primer (5
 
 
 
-CCC-
AATTATACTCTTGAAGAAGC-3
 
 
 
) for GAD65 transgenic
animals. Primers were spanning a 1.3 kb intron. 
 
 
 
-actin cDNA
was amplified as an internal control using intron spanning prim-
ers (5
 
 
 
-TGGAATCCTGTGGCATCCATGAAAC-3
 
 
 
) and (5
 
 
 
-
TAAAACGCAGCTCAGTAACAGTCCG-3
 
 
 
).
 
Generation of Recombinant GAD65
 
Full length murine GAD65 cDNA (with mutated active site)
was fused carboxyterminally to a 6*His tag and cloned into the
pET3a-expression vector (Novagen). The vector was trans-
formed into BL21DE3 Lys S cells. GAD65 expression was
induced by 4 mM IPTG. Baculovirus derived full-length
murineGAD65–6*His was produced according to a published
protocol with a baculovirus obtained from N. Sarvetnick (Scripps
Research Institute, La Jolla, CA; reference 17). Insect cells and
bacteria were lysed in buffer containing Guanidin-HCl buffer and
purified over Ni-NTA agarose (QIAGEN) according to standard
protocols. Protein was further purified on a 10% preparative
SDS-page gel and protein band was made visible with negative
Zn-Immidazol staining (Bio-Rad Laboratories). Recombinant
protein was electroeluted. Protein solution was successively re-
folded by dialysis against refolding buffer (5 mM reduced glu-
tathione, 25 mM Tris-HCl pH 7.4, 192 mM glycine, 0.02% SDS).
Concentration of SDS was subsequently lowered to 0.01 and
0.001%. The protein was then extensively dialyzed against PBS.
Protein solution was then incubated with End-X B15 beads (As-
sociates of Cape Cod, MA) to remove endotoxin. Finally solu-
tion was filtered and tested for endotoxin content using LAL-
lysate (Associates of Cape Cod). Endotoxin concentration was
below 0.3 U/ml. Quality and quantity of protein was tested with
SDS page gels, Coomassie stains, and Western blots using anti-
GAD6 monoclonal antibody.
 
Epitope Display
 
Thymi or spleens of 4-wk-old animals were minced with scis-
sors and digested with collagenase/dispase (0.2 mg/ml collagenase D,
0.2 mg/ml dispase I; Roche Diagnostics). Dendritic cells (DCs)
were enriched by density centrifugation on 16% (wt/wt) accu-
dens (Accurate Chemical & Scientific Corp.), stained with biotin-
antiCD11c and positively enriched using SA-Macs beads (Mil-
tenyi Biotech). 18 different GAD65 reactive T cell hybridomas
recognizing 11 I-A
 
g7
 
 restricted GAD65 epitopes (p78, p206, p217,
p221, p246, p286, p340, p479, p509, p524, p530) were tested
against the various DC preparations. We used two hybridomas
against some determinants and show the one with the best signal
to noise ratio in Fig. 1 D. GAD65 peptides used: p78–97 (KPS-
NSPKGDVNYAFLHATDL), p206–220 (TYEIAPVFVLLE-
YVT), p217–236 (EYVTLKKMREIIGWPGGSGD), p221–240
(LKKMREIIGWPGGSGDGIFS), p246–266 (SNMYAMLIAR-
YKMFPEVKEKG), p286–300 (KKGAAAIGIGTDSVI), p340–359
(VYGAFDPLLAVADISKKYK), p479–493 (EYLYTIIKNREG-
YEM), p509–528 (VPPSLRTLEDNEERMSRLSK), p524–543
(SRLSKVAPVIKARMMEYGTT).
10
 
4
 
 DCs were incubated for 48 h with 2 
 
  
 
10
 
5
 
 T cell hybrid-
omas in RPMI, 10% FCS, 100 U/ml penicillin/100 
 
 
 
g/ml strep-
tomycin, 55 
 
 
 
M 2-mercaptoethanol, and 0.3 mg/ml glutamine
(P/S/M/G). The IL-2 amount in the supernatant was tested withT
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a CTLL assay. Measurements were performed in triplicates and
peptide-loaded (10 
 
 
 
g/ml) DCs were used as positive controls to
test viability of the DC preparation and the responsiveness of the
hybridoma. Stimulation indices were calculated as cpm sample/
cpm control.
 
Testing for Tolerance
 
4 
 
  
 
10
 
5
 
 cells of draining popliteal and inguinal lymph nodes of
10-wk-old NOD mice 8 d after immunization with GAD65 (
 
E.
coli
 
 derived) in CFA or IFA injected into the foot pad were incu-
bated for 96 h with 10 
 
 
 
g/ml GAD65 (baculovirus derived) or
GAD65 peptides (10 
 
 
 
g/ml) in HL1 medium (BioWhittaker)
containing (P/S/M/G). Culture filtrate protein (CFP) was used as
positive control in recall assays (provided by College of Veteri-
nary Medicine and Biomedical Sciences, University of Colorado,
produced through funds from the National Institutes of Health,
National Institute of Allergy and Infectious Diseases, contract
NO1-AI-75320 entitled “Tuberculosis Research and Vaccine
Testing”). Culture was pulsed for final 18 h with [
 
3
 
H]-thymidine
and incorporated radioactivity was measured using scintillation
fluid in a 
 
 
 
-counter. Measurements were performed in triplicates.
Stimulation indices were calculated as cpm sample/cpm control.
 
Tetramer Staining
 
The SC-2 drosophila cell line that produces A
 
g7
 
-p286 mole-
cules was kindly provided by Luc Teyton (Scripps Research Insti-
tute, La Jolla, CA). Monomers of Ag7-p286 were purified as de-
scribed (18) and biotinylation of purified molecules was performed
with Bir A enzyme (Avidity) according to the manufacturer’s in-
structions. Biotinylated molecules were tetramerized at 4
 
 
 
C over-
night using PE-labeled streptavidin (Biosource International).
Single cell suspensions from lymph nodes were incubated with
0.5 mg/ml of streptavidin and Fc block in FACS buffer for 1 h at
room temperature (RT). Cells were then stained with PE-labeled
A
 
g7
 
-p286 tetramer (50 
 
 
 
g/ml) for 1 h at RT. For costaining of
surface markers APC-anti-CD4, FITC-anti-CD44, from BD
Biosciences were used, as well as PE-Cy7-anti-CD8 and PE-
Texas Red-anti-CD45R (B220) from Caltag. Exclusion of dead
cells was done by adding 0.1 
 
 
 
g/ml of Hoechst 33342 (Molecular
Probes, Inc.). Flow cytometry was performed using a MoFlow
instrument (DakoCytomation) and the data analyzed using Sum-
mit software (DakoCytomation). Analysis was gated (in depen-
dent order) on a lymphocyte gate in FSC versus SSC-plot, a
B220 negative and HOECHST negative gate, a CD4 positive
and CD8 negative gate, and analyzed in a CD4/tetramer PE
FACS-plot.
 
ELISPOT
 
5 
 
  
 
10
 
5
 
 draining lymph node cells were cultured in 200 
 
 
 
l
HL-1 medium (P/S/M/G) for 18 h at 37
 
 
 
C in Immunospot
M200 plates (Cellular Technologies Limited) coated with anti–
IFN-
 
 
 
 mAB (R4–6A2; BD Biosciences). Plates were washed and
incubated with biotin anti–IFN-
 
 
 
 (XMG1.2; BD Biosciences).
Spots were developed using streptavidin-alkaline phosphatase
(Mabtech), and NBT and BCIP were used as substrate (Prome-
gaI). Spots were analyzed on a ELISPOT reader (Cellular Tech-
nologies Limited).
Measurement of insulin-autoantibodies was performed by ra-
diobinding assay as recently described (19).
 
Transfer Experiments
 
Bone Marrow Transplants.
 
Bone marrow from 4–5-wk-old,
female GAD65 transgenic and NOD control mice was depleted
 
of erythrocytes by osmotic shock. T cells were removed using
biotinylated anti-CD3, anti-CD4, and anti-CD8 followed by neg-
ative selection using streptavidin-Macs beads (AmCell). 3 
 
  
 
10
 
6
 
T cell–depleted bone marrow cells were used to reconstitute 4-wk-
old lethally irradiated (2 
 
  
 
600 rads) female NOD mice. Prolifer-
ative response of draining lymph nodes cells 8 d after immuniza-
tion with GAD65 in CFA were tested 8 wk after reconstitution.
 
Thymic Chimeras.
 
4-wk-old NOD mice were thymecto-
mized. 2 wk later GAD65 transgenic or control thymi from 14-
d-old embryos were transplanted under the kidney capsule. After
another 2 wk mice were reconstituted with 3 
 
  
 
10
 
6
 
 T cell–
depleted bone marrow cells from NOD-Thy1.1 mice. 8 wk later
proliferative responses after immunization with GAD65 were
analyzed.
 
Histology
 
Thin section from formaldehyde fixed organs embedded in
paraffin were examined for the presence of insulitis after hema-
toxylin-eosin staining. Multiple sections were taken from differ-
ent levels and graded. Grade 0 (normal islets), Grade 1 (mononu-
clear infiltrate largely in the periphery in less than 25% of the
islet), Grade 2 (25% to 50% of the islet), Grade 3 (over 50% of the
islet), and Grade 4 (small retracted islet with minor infiltrate). 32–64
islets were scored per animal.
 
Statistical Analysis
 
All results of epitope display, proliferation-assays, ELISPOT
analysis, and tetramer-staining were analyzed by Student’s 
 
t
 
 test.
All differences reported in the results were significant (P 
 
 
 
 0.05).
The diabetes onset between transgenic and nontransgenic animals
was compared by Kaplan-Meier Analysis.
 
Results
 
GAD Transgenic Mice.
 
GAD65 displays a number of
particular features that may interfere with efficient presen-
tation of GAD-derived epitopes and thus may impede ef-
forts to experimentally induce specific tolerance. First, the
presence of a strongly hydrophobic NH
 
2
 
-terminal se-
quence (20) may interfere with efficient degradation. As no
epitopes were reported to derive from the NH
 
2
 
 terminus of
GAD65 the amino-terminal region containing 45 mostly
hydrophobic amino acids (3, 21–24) was deleted. Second,
in vitro translation assays in the presence of pancreatic mi-
crosomes showed that GAD65 cannot translocate effi-
ciently into the endoplasmic reticulum, most likely due to
the lack of a leader sequence (unpublished data). We tested
several leader constructs and found that amino-terminal fu-
sion of the H-2K
 
b
 
 leader resulted in improved translocation
(unpublished data). Next the enzymatically active site was
destroyed by mutagenesis (K396G) to prevent metabolic
effects of the transgene. Finally the construct was carboxy-
terminally fused to the LAMP-1 signaling sequence to
route the protein efficiently into the class II MHC peptide-
loading pathway (15; Fig. 1 A). Expression of the modified
sequence was controlled by a hybrid invariant chain pro-
moter to achieve efficient expression in antigen presenting
cells (16; Fig. 1 A).
Two independent GAD65 transgenic lines on the
NOD background were established showing comparableT
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mRNA expression in thymus, spleen, and lymph nodes
(Fig. 1 C). Besides expression in lymphoid tissue, signals
were detected in liver, lung, kidney, and brain (unpub-
lished data). Epitope presentation by DCs from GAD65
transgenic mice was tested using a panel of 18 GAD-spe-
cific T cell hybridomas covering all 11 I-A
 
g7
 
–restricted
epitopes reported to date (3, 22–24). As shown in Fig. 1 D
the epitopes p206, 217, 221, and 286 were efficiently pre-
sented by thymic DCs from GAD65 transgenic mice, and
weaker stimulation was found for the epitopes p78 and
p524. It is noteworthy that, in accord with data by others
(22, 23), some of the epitopes that were not presented can
only be defined by stimulating T cells with peptides but
are not displayed when APCs such as NOD splenocytes or
DCs are incubated with GAD65 protein. In the latter case
only epitopes 206, 217, 221, and 286 are presented (un-
published data) and it remains to be shown that in vivo
any of the other epitopes is even generated from endoge-
nous GAD65 (24). Taken together, all epitopes that can
reasonably be believed to be derived from GAD65 in vivo
were presented by DCs in the GAD65 transgenic mice. In
the GAD transgenic mice, total thymocytes and thy-
mocyte subsets defined by CD4 and CD8 were as in non-
transgenic littermate controls as were T and B lympho-
cytes, DCs, and macrophages in spleen and lymph node
(unpublished data).
 
GAD65-specific Tolerance.
 
GAD65-specific tolerance
was tested in nonprimed animals (proliferation-assay/
ELISPOT/tetramer-staining) and after immunization with
recombinant murine GAD65 produced in an 
 
E. coli
 
 sys-
tem. Unprimed cells from spleen and pancreatic lymph
nodes displayed no consistent response upon culture in the
presence of GAD65 or its peptide epitopes as measured by
proliferation or ELISPOT analysis. Similar difficulties in
obtaining reproducible “spontaneous” responses of non-
primed T cells have been reported by other groups (25,
26). To achieve a more reliable assessment of GAD-spe-
cific T cell responses animals were immunized with re-
combinant GAD65 protein produced in an 
 
E. coli
 
 system.
Proliferative recall responses were then tested using either
GAD65 peptides or whole protein. GAD65 protein used
for restimulation was produced in a baculoviral expression
 
Figure 1.
 
Characterization of GAD65 transgenic mice. (A) Diagram of
the transgenic GAD65 construct. (B) Details of the transgenic construct
being used. (a) K
 
b
 
-leader (underlined) fusioned with amino acid 46 (
 
***
 
)
of the GAD65 protein. (b) Amino acid 585 (
 
***
 
) of GAD65 fusioned with
the transmembrane, cytoplasmic tail of the LAMP1 protein (underlined).
The lysosomal targeting signal is in boldface. XXX indicate stop codons.
(C) Expression of GAD65 mRNA in lymphoid compartments of 6-wk-
old female NOD or GAD65-tg. mice by reverse transcriptase PCR using
fivefold serial dilutions. 
 
 
 
-actin cDNA was amplified as an internal con-
trol. (D) Epitope display of thymic dendritic cells. 11 different GAD65
reactive T cell hybridomas recognizing I-A
 
g7
 
 restricted GAD65 epitopes
were tested against thymic DCs from GAD65tg. (black bars) and NOD
control mice (open bars). Stimulation indices were calculated as cpm sam-
ple/cpm control. Background values were between 300 cpm to 3,300
cpm/well depending on the hybridoma used. Stimulation indices for pep-
tide pulsed DCs were between 10–70 for the hybridomas shown.T
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system to prevent recall responses to contaminants from
the 
 
E. coli
 
 preparation used as an immunogen. In nontrans-
genic mice, the qualitative spectrum (responses against
GAD65 protein and p206, p217, p221, p286) of the
immune response was similar after immunization with
GAD65 in either complete or incomplete Freund’s adju-
vants ruling out an alteration of the GAD65 epitope hier-
archy by the use of agents stimulating APCs (Fig. 2 A).
GAD65tg mice exhibited tolerance to the entire GAD65
protein as well as to all tested peptide epitopes (Fig. 2, B
and C). Although GAD65-specific tolerance in NOD
mice could only be induced by transgenic expression of a
modified form of GAD65, tolerance was seen in recall as-
says using the entire, unmodified GAD65 protein, thereby
excluding that the modifications altered epitopes that can
be derived from the wild-type protein. No responses to
epitopes p78, p246, p340, p479, p509, and p530 were de-
tected in either immunized GAD transgenic or NOD mice
indicating that these epitopes are only recognized after spe-
cific immunization/stimulation with the respective pep-
tides but are not part of the normal T cell response to the
GAD protein.
Staining with an I-A
 
g7
 
-GAD65-p286 tetramer (18) of
draining lymph nodes 8 d after immunization with
GAD65 protein demonstrated the absence of p286-reac-
tive cells in GAD transgenic mice but not in NOD control
mice (Fig. 3, A–C). Likewise no IFN-
 
 
 
–producing cells
were found in draining lymph nodes of immunized
GAD65 transgenic mice by ELISPOT assays (Fig. 3 D).
These results were reproducible in all 10 GAD65 trans-
genic mice that were tested.
As all MHC class II–positive APC can express the modi-
fied form of GAD65 it was of interest to dissect the respec-
tive roles of hematopoietic APC versus thymic epithelial
cells for tolerance induction. Transplantation of GAD65tg.
bone marrow into irradiated NOD mice resulted in
GAD65-specific tolerance indicating that expression by he-
matopoietic cells was sufficient for tolerance induction (Fig.
4 A). Likewise, transplantation of irradiated GAD65tg E14
fetal thymi into NOD mice and subsequent reconstitution
with nontransgenic bone marrow resulted in GAD-specific
tolerance (Fig. 4 B). This indicates that GAD expression by
thymic epithelial cells suffices to induce tolerance in devel-
oping T cells.
Figure 2. T cell responses of GAD65
transgenic animals against GAD65
and its peptide epitopes. (A) Prolifera-
tion assay of draining lymph node
cells of 10-wk-old NOD mice 8 d af-
ter immunization with GAD65 in
complete (black bars) and incomplete
Freund’s adjuvants (open bars) into
foot pads. Representative result from
five independent experiments. (B and
C) Proliferative response of draining
lymph node cells of NOD control
mice (black bars) and two GAD65
transgenic lines (gray bars: line 14;
open bars: line 29) to GAD65 and its
peptide epitopes (all 10  g/ml) 8 d
after immunization with GAD65 in
CFA. CF, culture filtrate protein of
M. tuberculosis as positive control. (C)
Titration of the positive proliferative
recall responses as seen in B. ( 
NOD controls;   GAD65tg. line 14;
  GAD65tg. line 29).T
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Figure 3. T cell responses of
GAD65 transgenic animals against
GAD65 and its peptide epitopes. (A)
Percent of CD4  cells from lymph
nodes (draining lymph nodes: open
bars; mesenteric lymph nodes: gray
bars) of NOD control and
GAD65tg. mice 8 d after immuniza-
tion with GAD65 in CFA as mea-
sured by FACS® analysis. Percent
values of background tetramer stain-
ing (animals just immunized with
CFA [0.034–0.062%]) were sub-
tracted from each sample (n    4).
(B) Representative FACS-plot of
I-Ag7-p286  tetramer staining of
lymph node cells from NOD con-
trol mice (B) and GAD65tg. mice
(C) immunized with GAD65 in
CFA (top two panels) or CFA alone
(bottom two panels). (D) Number of
IFN- –secreting cells from draining
lymph nodes of NOD-control (open
bars) and GAD65tg. mice (gray bars)
after immunization with GAD65 as
determined by ELISPOT analysis.T
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Insulitis/Diabetes.
 
In GAD65 tolerant mice, we investi-
gated anti-  cell immunity in order to find out whether
recognition GAD represents an essential event for the de-
velopment of diabetes. In spite of GAD-specific tolerance,
titers of insulin-autoantibodies, an accepted marker of a
spontaneous anti– -cell immune response in the NOD
mouse (19), were similar in 14-wk-old GAD65tg.
and NOD control mice (Fig. 5 A). More importantly,
GAD65tg mice exhibited a similar incidence and severity
of insulitis as an early sign of the autoimmune disease at ten
weeks of age (Fig. 5 B). Furthermore, GAD65 transgenic
females developed IDDM with the same incidence and ki-
netics as female NOD mice (Fig. 5 C). The results were
similar for two independent founder lines of GAD65 trans-
genic mice.
We conclude therefore that GAD is not an essential au-
toantigen for either initiating or maintaining diabetes in
NOD mice.
Discussion
The protocol described here, is the first to induce GAD-
specific tolerance in NOD mice. These findings argue
against the notion that NOD mice may be generally re-
fractory to tolerance induction against autoantigens and
that this is the reason why diabetes develops in these mice
(13, 14). While it is difficult to rule out subtle differences
in susceptibility to tolerance induction in NOD mice, ex-
pression of modified transgenic GAD65 resulted in a ro-
bust state of CD4  T cell tolerance in this mouse strain,
thereby enabling us to conclusively investigate the role of
GAD as an autoantigen in the natural development of
IDDM in NOD mice. Tolerance was demonstrated to the
entire, unmodified GAD65 protein indicating tolerance to
all epitopes that can be naturally derived from this protein.
In spite of specific tolerance insulitis and diabetes occurred
with normal kinetics indicating that GAD is not an es-
sential autoantigen in the pathogenesis of diabetes. Al-
though tolerance was demonstrated in proliferation assays,
ELISPOT, and MHC II-tetramer staining, we cannot
completely rule out that there were some GAD65-reac-
tive, low-affinity T cells, which cannot be detected by our
assays. According to the titration in Fig. 2 C, these cells
would be of extremely low affinity and thus of question-
able relevance. On the other hand, the NOD mouse con-
tains a substantial number of highly reactive anti-GAD
T cells as shown by ELISPOT and proliferation assays that
were deleted in transgenic mice (12, 13). If T cells against
GAD had a major role in the pathogenesis of IDDM in the
NOD mouse one would expect these high affinity T cells
to be of greater relevance than putative low affinity T cells.
Yet deletion of these high affinity cells did not result in any
delay of diabetes onset.
We also cannot rule out that the GAD transgenic mice
still contain some class I MHC-restricted, GAD65-specific
T cells as reported by Quinn (27). However, it is not clear
at present whether such cells can be activated in vivo and
transfer experiments failed to show that these cells cause di-
abetes. In any case, it is quite likely that such cells would be
tolerized by the numerous cells in the GAD transgenic
mice that express the protein intracellularly.
One needs to explain why on the one hand various regi-
mens of administration of GAD (intrathymic, intranasal,
oral, intravenous) resulted in delayed onset of diabetes (3, 4,
7, 28) while on the other hand tolerogenic expression of
transgenic GAD had no effect on the onset of disease. We
consider it likely that dominant tolerance is induced by the
former approaches resulting in the generation of regulatory
cells that may locally suppress immune responses against a
variety of   cell–derived antigens in a bystander fashion.
Importantly, such a modulation of diabetes on the basis of
dominant tolerance toward GAD cannot be taken to indi-
cate an essential role of GAD65 as target antigen in the nat-
ural disease process. In contrast, transgenic expression of
GAD most likely resulted in deletional (recessive) toler-
ance, i.e., elimination of GAD-specific T cells rather than
generation of regulatory. This conclusion is supported by
Figure 4. Cells mediating GAD65-specific tolerance. (A) NOD mice
were lethally irradiated and reconstituted with bone marrow from NOD
(open bars) or GAD65tg. mice (gray bars). Proliferative recall responses
after immunization with GAD65. CF, culture filtrate protein of M. tuber-
culosis as positive control. Representative result out of three independent
experiments. (B) Thymectomized NOD mice were engrafted with E14
fetal thymi from NOD (open bars) or GAD65tg. mice (gray bars) and, af-
ter ablative irradiation, reconstituted with NOD bone marrow. Prolifera-
tive recall responses after immunization with GAD65.T
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the absence of detectable frequencies of tetramer-positive
cells in draining lymph nodes of immunized GAD-trans-
genic animals. With regard to the possible induction of reg-
ulatory T cells in our transgenic mice, we did not observe
suppression or delay of diabetes upon cotransfer of 2   107
splenocytes from GAD65 transgenic mice with 2   107 di-
abetogenic T cells into irradiated NOD mice compared
with the cotransfer of 2   107 splenocytes from age
matched control mice (containing comparable numbers of
CD4 CD25  and CD4 CD25  T cells) with diabetogenic
splenocytes. In contrast development of diabetes was pre-
vented by cotransfer of 2   107 thymocytes (positive con-
trol) from 4-wk-old NOD mice as previously reported (29;
unpublished data).
Whatever the reason for tolerance in the GAD trans-
genic mice is, the fact that T cells do not respond to GAD
and disease progresses normally clearly indicate that GAD is
not an essential autoantigen. In this context it is interesting
to note that CD4  T cells from GAD65-specific T cell re-
ceptor transgenic NOD mice are not diabetogenic (30).
Our data suggest that the protection observed in the
GAD-antisense experiments has no immunological basis
(9), i.e., the absence of a GAD-specific T cell response is
most likely not the reason for the observed protection. In
this context it would be of interest to find out in which
way pancreatic islet cells might be protected from immu-
nological attack by GAD antisense transgenic mice (9).
While the above experiments ruled out GAD as an au-
toantigen essential for the development of diabetes, they
have documented that it is feasible to induce antigen-spe-
cific tolerance in NOD mice. The same approach might be
used to determine whether tolerance to other individual
 -cell–specific autoantigens such as preproinsulin can pre-
vent diabetes or whether tolerance to a combination of such
autoantigens can be used to interfere with the disease.
Transgenic NOD mice may be useful to identify such anti-
gens which through presentation by thymic stroma as well
as by bone marrow–derived hemopoietic cells can induce
specific tolerance. Future research in this field will be im-
portant to develop antigen-specific intervention protocols
Figure 5. Spontaneous anti-insulin immune response, insulitis, and
IDDM in GAD65 transgenic mice. (A) Insulin-autoantibodies in 14-wk-
old, female GAD transgenic, NOD mice as well as in controls (NOR,
non obese diabetes resistant mice; C57/B6, Balb/c mice) measured by ra-
diobinding assay. There was no statistical difference between 14w old
NOD mice and GAD65-tg. animals. (B) Histological grading of insulitis
in pancreas sections of 4 and 10 week old mice (n   4 per group). (C)
Cumulative incidence of development of IDDM in NOD mice (n   30;
black curve) and GAD65 transgenic mice (n   34; gray curve). Data of
two independent GAD65 founder lines were combined. There was no
statistical difference in diabetes onset between transgenic and nontrans-
genic mice according to Kaplan-Meier Analysis.T
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for the treatment of patients at risk of developing IDDM or
for patients receiving islet cell transplantation.
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